IP Library Granted Patent US 10,709,711
Granted Patent B2
US 10,709,711 · App. 16/228,308 · Granted Jul 14, 2020

Highly active anti-neoplastic and anti-proliferative agents

Inventors: Jay Copeland Strum (Hillsborough, NC); John Emerson Bisi (Apex, NC); Patrick Joseph Roberts (Durham, NC); Francis Xavier Tavares (Durham, NC)
Assignee: G1 Therapeutics, Inc.
A61K31/527A61K31/529A61K31/5377A61K47/545A61K47/6803A61K47/6867A61K51/0459A61K51/0468C07D487/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,709,711
App. No.
16/228,308
Granted
Jul 14, 2020
Kind
B2
Abstract

This invention is in the area of improved compounds and methods for treating selected cancers and hyperproliferative disorders.

Claims (16)

1. A method of treating T-cell leukemia in a human in need thereof comprising administering to the host an effective amount of a compound having the structure:

or a pharmaceutically acceptable salt thereof

wherein the T-cell leukemia is acute lymphoblastic leukemia (ALL).

2. The method of claim 1 , wherein the compound, or its pharmaceutically acceptable salt thereof, is administered in combination with a second active agent.

3. A method of treating T-cell leukemia in a human in need thereof comprising administering to the host an effective amount of a compound having the structure:

or a pharmaceutically acceptable salt thereof

wherein the T-cell leukemia is acute lymphoblastic leukemia.

4. The method of claim 3 , wherein the compound, or its pharmaceutically acceptable salt thereof, is administered in combination with a second active agent.

5. A method of treating T-cell lymphoma in a human in need thereof comprising administering to the host an effective amount of a compound having the structure:

or a pharmaceutically acceptable salt thereof

wherein the T-cell lymphoma is lymphoblastic lymphoma.

6. The method of claim 5 , wherein the compound, or its pharmaceutically acceptable salt thereof, is administered in combination with a second active agent.

7. A method of treating T-cell lymphoma in a human in need thereof comprising administering to the host an effective amount of a compound having the structure:

or a pharmaceutically acceptable salt thereof

wherein the T-cell lymphoma is lymphoblastic lymphoma.

8. The method of claim 7 , wherein the compound, or its pharmaceutically acceptable salt thereof, is administered in combination therapy with a second active agent.

Assignments (11)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 5, 2024
From: G1 THERAPEUTICS, INC.
To: PHARMACOSMOS A/S
Reel/Frame 069501/0773 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 5, 2024
From: PHARMACOSMOS A/S
To: PHARMACOSMOS HOLDING A/S
Reel/Frame 069501/0791 →
RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Sep 19, 2024
From: HERCULES CAPITAL, INC., AS COLLATERAL AGENT
To: G1 THERAPEUTICS, INC.
Reel/Frame 068996/0001 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE ADDRESS PREVIOUSLY RECORDED AT REEL: 055725 FRAME: 0654. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Mar 29, 2021
From: TAVARES, FRANCIS X.
To: G1 THERAPEUTICS, INC.
Reel/Frame 055748/0173 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 25, 2021
From: TAVARES, FRANCIS X.
To: G1 THERAPEUTICS, INC.
Reel/Frame 055725/0654 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 19, 2021
From: STRUM, JAY COPELAND; BISI, JOHN EMERSON; ROBERTS, PATRICK JOSEPH
To: G1 THERAPEUTICS, INC.
Reel/Frame 055650/0951 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded May 29, 2020
From: G1 THERAPEUTICS, INC.
To: HERCULES CAPITAL, INC., AS COLLATERAL AGENT
Reel/Frame 052795/0074 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 10, 2020
From: SHARPLESS, NORMAL E.; BISI, JOHN EMERSON; ROBERTS, PATRICK JOSEPH; STRUM, JAY COPELAND; TAVARES, FRANCIS X.
To: G1 THERAPEUTICS, INC.
Reel/Frame 052073/0387 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 10, 2020
From: SHARPLESS, NORMAN E.; BISI, JOHN EMERSON; ROBERTS, PATRICK JOSEPH; STRUM, JAY COPELAND; TAVARES, FRANCIS XAVIER
To: G1 THERAPEUTICS, INC.
Reel/Frame 052073/0400 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 10, 2020
From: SHARPLESS, NORMAN E.; BISI, JOHN EMERSON; ROBERTS, PATRICK JOSEPH; STRUM, JAY COPELAND; TAVARES, FRANCIS XAVIER
To: G1 THERAPEUTICS, INC.
Reel/Frame 052073/0415 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 10, 2020
From: SHARPLESS, NORMAN E.; BISI, JOHN EMERSON; ROBERTS, PATRICK JOSEPH; STRUM, JAY COPELAND
To: G1 THERAPEUTICS, INC.
Reel/Frame 052137/0273 →
Cited By (1)
US 12,527,798